ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease

Clinical Cancer Research

Volumn 8, Issue 10, 2002, Pages 3054-3064

  Gilbertson, Richard J ^a   Bentley, Lyndsay ^a   Hernan, Roberto ^a   Junttila, Teemu T ^b,c   Frank, Adrian J ^a   Haapasalo, Hannu ^d   Connelly, Michele ^a   Wetmore, Cynthia ^a   Curran, Tom ^a   Elenius, Klaus ^b   Ellison, David W ^e,f  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERBB RECEPTOR; KI 67 ANTIGEN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; WAY 177820;

ANAPLASTIC CARCINOMA; ARTICLE; CELL PROLIFERATION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG TARGETING; ENZYME PHOSPHORYLATION; EPENDYMOMA; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SURVIVAL RATE; WESTERN BLOTTING;

BLOTTING, SOUTHERN; BLOTTING, WESTERN; CELL DIVISION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EPENDYMOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0036793917     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bouffet, E., Perilongo, G., Canete, A., and Massimino, M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med. Pediatr. Oncol., 30: 319-331, 1998.
2. Robertson, P. L., Zeltzer, P. M., Boyett, J. M., Rorke, L. B., Allen, J. C., Geyer, J. R., Stanley, P., Li, H., Albright, A. L., McGuire-Cullen, P., Finlay, J. L., Stevens, K. R. Jr., Milstein, J. M., Packer, R. J., and Wisoff, J. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Study Group. J. Neurosurg., 88: 695-703, 1998.
3. Horn, B., Heideman, R., Geyer, R., Pollack, I., Packer, R., Goldwein, J., Tomita, T., Schomberg, P., Ater, J., Luchtman-Jones, L., Rivlin, K., Lamborn, K., Prados, M., Bollen, A., Berger, M., Dahl, G., McNeil, E., Patterson, K., Shaw, D., Kubalik, M., and Russo, C. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J. Pediatr. Hematol. Oncol., 21: 203-211, 1999.
4. Grill, J., Le Deley, M. C., Gambarelli, D., Raquin, M. A., Couanet, D., Pierre-Kahn, A., Habrand, J. L., Doz, F., Frappaz, D., Gentet, J. C., Edan, C., Chastagner, P., and Kalifa, C.; French Society of Pediatric Oncology. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J. Clin. Oncol., 19: 1288-1296, 2001.
5. Wiestler, O. D., Schiffer, D., Coons, S. W., Prayson, R. A., and Rosenblum, M. K. Ependymoma. In: P. Kleihues and W. K. Cavenee (eds.), World Health Organisation Classification of Tumors. Pathology and Genetics of Tumors of the Nervous System, pp. 72-77. Lyon, France: IARC Press, 2000.
6. Schiffer, D., and Giordana, M. T. Prognosis of ependymoma. Childs Nerv. Syst., 14: 357-361, 1998.
7. Needle, M. N., Goldwein, J. W., Grass, J., Cnaan, A., Bergman, I., Molloy, P., Sutton, L., Zhao, H., Garvin, J. H., Jr., and Phillips, P. C. Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer (Phila.), 80: 341-347, 1997.
8. Bijlsma, E. K., Voesten, A. M., Bijleveld, E. H., Troost, D., Westerveld, A., Merel, P., Thomas, G., and Hulsebos, T. J. Molecular analysis of genetic changes in ependymomas. Genes Chromosomes Cancer, 13: 272-277, 1995.
9. von Haken, M. S., White, E. C., Daneshvar-Shyesther, L., Sih, S., Choi, E., Kalra, R., and Cogen, P. H. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer, 17: 37-44, 1996.
10. Mazewski, C., Soukup, S., Ballard, E., Gotwals, B., and Lampkin, B. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet., 113: 1-8, 1999.
11. Hirose, Y., Aldape, K., Bollen, A., James, C. D., Brat, D., Lamborn, K., Berger, M., and Feuerstein, B. G. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am. J. Pathol., 158: 1137-1143, 2001.
12. Lamszus, K., Lachenmayer, L., Heinemann, U., Kluwe, L., Finckh, U., Hoppner, W., Stavrou, D., Fillbrandt, R., and Westphal, M. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int. J. Cancer., 91: 803-808, 2001.
13. Carter M., Nicholson J., Ross F., Crolla J., Allibone R., Balaji V., Perry R., Walker D., Gilbertson R., and Ellison D. Genetic abnormalities detected in histological variants of ependymoma by comparative genomic hybridisation. Br. J. Cancer, in press, 2002.
14. Olayioye, M., A., Neve, R. M., Lane, H. A., and Hynes, N. E. The ERBB signaling network: receptor heterodimerization in development and cancer. EMBO J., 19: 3159-3167, 2000.
15. Yarden, Y., and Sliwkowski, M. X. Untangling the ERBB signalling network. Nat. Rev. Mol. Cell Biol., 2: 127-137, 2001.
16. Burden, S., and Yarden, Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron, 18: 847-855, 1997.
17. Lambert de Rouvroit, C., and Goffinet, A. M. A new view of early cortical development. Biochem. Pharmacol., 56: 1403-1409, 1998.
18. Buonno, A., and Fischbach, G. D. Neuregulin and ERBB receptor signaling pathways in the nervous system. Curr. Opin. Neurobiol., 11: 287-296, 2001.
19. Gerecke, K. M., Wyss, J. M., Karavanova, I., Buonno, A., and Carroll, S. L. ERBB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult central nervous system. J. Comp. Neurol., 433: 86-100, 2001.
20. Gilbertson, R. J., Perry, R. H., Kelly, P. J., Pearson, A. D., and Lunec, J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res., 57: 3272-3280, 1997.
21. Gilbertson, R. J., Jaros, E. A. B., Perry, R. H., and Pearson, A. D. J. Percentage mitotic index: a new prognostic factor for childhood medulloblastoma. Eur. J. Cancer, 33: 609-615, 1997.
22. Gilbertson, R. J., Hernan, R., Pietsch, T., Pinto, L., Scotting, P., Allibone, R., Ellison, D., Perry, R. H., Pearson, A. D., and Lunec, J. Novel ERBB4 receptor spliced variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer, 31: 288-294, 2001.
23. Gilbertson, R. J., Hernan, R., Wickramasinghe, C., Balaji, V., Hunt, D., Jones-Wallace, D., Crolla, J., Perry, R. H., Lunec, J., Pearson, A. D., and Ellison, D. Molecular stratification of disease risk in medulloblastoma. Br. J. Cancer, 85: 705-712, 2001.
24. Bennetto, L., Foreman, B., Harding, R., Hayward, R., Ironside, J., Love, S., and Ellison, D. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropath. Appl. Neurobiol., 24: 434-440, 1998.
25. Rabindran, S. K., Discafani, C. M., Floyd, M. B., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., Reich, M. F., Rosfjord, E., Shen, R., Shi, S., Tsou, H-W., Wang, Y-F., and Wissner A. Antitumor activity of compound 820 in xenografts: an orally active irreversible inhibitor of the Her-2 receptor tyrosine kinase. Proc. Am. Assoc. Cancer Res., 43: 1001, 2002.
26. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
27. Ritter, A. M., Hess, K. R., McLendon, R. E., and Langford, L. A. Ependymomas: MIB-1 proliferation index and survival. J. Neurooncol., 40: 51-57, 1998.
28. Rushing, E. J., Brown, D. F., Hladik, C. L., Risser, R. C., Mickey, B. E., and White, C. L. Correlation of bcl-2, p53 and MIB-1 expression with ependymoma grade and subtype. Mod. Pathol., 11: 464-470, 1998.
29. Prayson, R. Clinicopathological study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann. Diagn. Pathol., 3: 11-18, 1999.
30. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639-2648, 1999.
31. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
32. Kainulainen, V., Sundvall, M., Maatta, J. A., Santiestevan, E., Klagsbrun, M., and Elenius, K. A natural ERBB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J. Biol. Chem., 275: 8641-8649, 2000.
33. Flores, A. I., Mallon, B. S., Matsui, T., Ogawa, W., Rosenzweig, A., Okamoto, T., and Macklin, W. B. Akt-mediated survival of oligodendrocytes induced by neuregulins. J. Neurosci., 20: 7622-7630, 2000.
34. Elenius, K., Corfas, G., Paul, S., Choi, C. J., Rio, C., Plowman, G. D., and Klagsbrun, M. A novel juxtamembrane domain isoform of HER4/ERBB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J. Biol. Chem., 272: 26761-26768, 1997.
35. Sawyer, C., Hiles, I., Page, M., Crompton, M., and Dean, C. Two ERBB-4 transcripts are expressed in normal breast and in most breast cancers. Oncogene, 17: 919-924, 1998.
36. Elenius, K., Choi, C. J., Paul, S., Santiestevan, E., Nishi, E., and Klagsbrun, M. Characterization of a naturally occurring ERBB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene, 18: 2607-2615, 1999.
37. Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., and Yoshinaga, S. K. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem., 271: 3884-3890, 1996.
38. Pinkas-Kramarski, R., Shelly, M., Guarino, B. C., Wang, L. M., Lyass, L., Alroy, I., Alimandi, M., Kuo, A., Moyer, J. D., Lavi, S., Eisenstein, M., Ratzkin, B. J., Seger, R., Bacus, S. S., Pierce, J. H., Andrews, G. C., Yarden, Y., and Alamandi M. ERBB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol. Cell. Biol.; 18: 6090-6101, 1998.